Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer

Phase 2 Completed 17 enrolled National Cancer Institute (NCI)

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer. Linsitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start: 2012-02
Primary completion: 2012-11
Completion: 2012-11

Outcome

Missed primary endpoint

paper All but two patients discontinued therapy secondary to PSA progression, which met the predefined futility criteria and led to early termination of this study. PMID 29476383 ↗

paper Conclusions Single-agent linsitinib was safe and well tolerated but failed to show activity in men with mCRPC. PMID 29476383 ↗

Publications

Barata P, Cooney M, Tyler A, Wright J, Dreicer R, Garcia JA. A phase 2 study of OSI-906 (linsitinib, an insulin-like growth factor receptor-1 inhibitor) in patients with asymptomatic or mildly symptomatic (non-opioid requiring) metastatic castrate resistant prostate cancer (CRPC). Invest New Drugs. 2018 Jun;36(3):451-457. doi: 10.1007/s10637-018-0574-0. Epub 2018 Feb 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	linsitinib	Small molecule	150 mg	Oral